Indocanine Green as Tracer for Lymph Nodes Dissection in Station 253
Rectal Carcinoma, Sigmoid Colon Carcinoma
About this trial
This is an interventional diagnostic trial for Rectal Carcinoma focused on measuring ICG, 253 lymph nodes, rectal carcinoma, sigmoid colon carcinoma
Eligibility Criteria
Inclusion Criteria:
(1)18-80 years of age (2)American Society of Anesthesiologists (ASA) class 1-3 (3)single rectal or sigmoid colon carcinoma confirmed pathologically by endoscopic biopsy (4)planned laparoscopic radical resection (5)Written informed consent
Exclusion Criteria:
- previous abdominal tumor surgery
- women who are pregnant or breast feeding
- emergency patients with obstruction or perforation
- T4b cancer evaluated by CT or MRI or endoscopic ultrasonography
- pelvic or distant metastasis
- T1 cancer planned local excision
- allergic constitution patients
Sites / Locations
- Nanfang Hospital, Southern Medical UniversityRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
No Intervention
ICG group
CLgroup
Patients in the ICG group will undergo endoscopic injection of ICG 4 hours before surgery. The ICG powder will be dissolved in 2.5mg/ml of sterile water. ICG will be injected along the submucosa at 4 points around the primary tumor,for a total volume of 10ml.
Patients in the CL group will undergo routine laparoscopic lymph nodes dissection instead of using any tracer.